[Fam-] Trastuzumab Deruxtecan Granted FDA Priority Review for Treatment of Patients with HER2-positive Metastatic Breast Cancer

17 October 2019 -- AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for [fam-] trastuzumab deruxtecan...

Source: Drugs.com - Clinical Trials - October 17, 2019 Category: Pharmaceuticals Source Type: clinical trials